Update following statement by NIAID on AZD1222 US Phase III trial data
|
23 March 2021 |
AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis
|
22 March 2021 |
UK and EU regulatory agencies confirm COVID-19 Vaccine AstraZeneca is safe and effective
|
18 March 2021 |
Agreement builds on an earlier announcement that included support for the clinical development and supply of the treatment
|
16 March 2021 |
Update on the safety of COVID-19 Vaccine AstraZeneca
|
14 March 2021 |
AstraZeneca advances mass global rollout of COVID-19 vaccine through COVAX
|
04 March 2021 |
AstraZeneca COVID-19 vaccine authorised for emergency use by the World Health Organization
|
16 February 2021 |
AstraZeneca and IDT Biologika sign letter of intent to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity
|
10 February 2021 |
COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials
|
03 February 2021 |
COVID-19 Vaccine AstraZeneca recommended for use in the EU
|
29 January 2021 |